• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»IBS

Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO

By Pallavi Madhiraju on April 30, 2026   Medical Devices & Diagnostics  

Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO

Gut diagnostics need proof, not buzz. Gemelli Biotech’s DDW 2026 visibility could test whether IBS and SIBO care is ready for precision tools.

Recent Posts

  • Why Premier Biotech’s NexScreen and TransMed acquisitions could reshape rapid drug testing
  • Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab
  • Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data
  • Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models
  • Why AngioDynamics stock investors should watch NanoKnife’s move into benign prostate disease
  • Canada’s healthcare market faces a turning point as Alberta prepares dual-practice surgery launch
  • AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
  • Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
  • CureGene targets clopidogrel variability as evategrel begins a critical United States study
  • GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
  • Can uniQure turn the FDA’s AMT-130 reversal into a Huntington’s disease approval?
  • Replicate Bioscience wins Gates Foundation support for an ambitious TB vaccine strategy
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes